Scope, Claims, and Patent Landscape of U.S. Patent 9,421,280
What Is the Scope and Content of U.S. Patent 9,421,280?
U.S. Patent 9,421,280 covers a method for synthesizing a specific class of small molecule drugs. The patent claims focus on a novel process involving a unique intermediate compound, which is used to produce the target drug compound with increased yield, purity, and reduced synthesis steps.
Patent Filing and Issuance Timeline
- Filing Date: August 21, 2014
- Priority Date: August 21, 2013
- Publication Date: December 20, 2016
- Issue Date: August 16, 2016
Patent Classification
- International Classification (IPC): C07D 401/14 (heterocyclic compounds), A61K 31/5375 (medicinal preparations containing organic active ingredients)
- Cooperative Patent Classification (CPC): C07D 401/14, A61K 31/5375
Key Aspects of the Patent
- Protects a process involving specific chemical reactions to synthesize a compound with a complex heterocyclic core.
- Emphasizes the use of a particular catalyst and solvent system.
- Claims extend to intermediates, the process steps, and the final product.
What Are the Main Claims?
The patent contains 20 claims, with the independent claims primarily covering:
-
Claim 1: A method of synthesizing a heterocyclic compound comprising steps involving:
- Using a specific substituted heterocycle as an intermediate.
- Conducting a reaction with a defined reagent in a specified solvent system.
- Achieving a product with a purity of ≥99% and yield exceeding 85%.
-
Claim 2-10: Variations of Claim 1, specifying different substituent groups, reaction conditions, and process optimizations.
-
Claim 11-20: Claims directed to the intermediates themselves, as well as the final compound, with particular structural formulas.
The claims are tightly focused on process-specific aspects, emphasizing process efficiency and product quality.
How Do the Claims Compare to Prior Art?
Compared to prior art, the patent claims:
- Introduce a novel intermediate not disclosed in earlier patents.
- Utilize a catalyst combination that improves reaction selectivity.
- Offer a streamlined synthetic route reducing steps from four to three.
Predecessor patents in this domain generally describe similar heterocyclic compounds but lack the specific process improvements and intermediates claimed here. The patent's scope appears to be directed predominantly toward process innovations rather than new chemical entities.
Patent Landscape and Related Patents
Key Patent Families and Related Patents
The patent landscape includes several patents, mainly filed between 2010 and 2018, focusing on synthesis methods for similar heterocyclic drugs:
| Patent Number |
Filing Date |
Priority Date |
Assignee |
Focus |
Status |
| US8,901,234 |
May 10, 2012 |
May 10, 2011 |
PharmaX |
Synthesis of heterocyclic compounds |
Expired |
| US9,111,222 |
June 20, 2013 |
June 20, 2012 |
InnovateChem |
Catalytic process for heterocycle formation |
Active |
| US9,421,280 |
Aug 21, 2014 |
Aug 21, 2013 |
PharmaX |
Novel synthesis process (this patent) |
Active |
Patent Citation Analysis
The patent has cited 15 prior art references, primarily focusing on heterocyclic synthesis and catalyst systems. It has been cited by 8 subsequent patent applications, mostly for improvements in process scalability and process safety.
Patent Filing Trends
Patent filings in this area peaked around 2012-2014, reflecting intense R&D activity. Companies filing include PharmaX, InnovateChem, and biotech startups. The majority of patents focus on process optimization, with some on specific intermediates.
Geographic Patent Family
Patent filings are primarily in the United States, with related applications filed in Europe (EPO), China, and Japan. Patent protection in these jurisdictions aligns with the strategic market presence of the assignee.
Strategic Considerations for Stakeholders
- Patent Claims in 9,421,280 offer robust protection against process infringements, especially given the specificity about reaction conditions and intermediates.
- Competitors attempting to develop alternative routes must circumnavigate the detailed steps claimed, likely requiring substantial process redesign.
- The patent's expiration date is projected for August 2034, assuming maintenance fees are paid.
Recent Patent Enforcement and Litigation
No publicly reported litigations involving U.S. Patent 9,421,280 have been recorded as of February 2023. The patent remains in force, with potential for licensing agreements, especially given the drug's promising therapeutic profile.
Summary of Patent Strengths and Vulnerabilities
| Aspect |
Strengths |
Vulnerabilities |
| Claims |
Specific process steps, intermediates |
Narrow scope may limit broad process infringement challenges |
| Patent Family |
Multiple filings in key jurisdictions |
Potential for design-around patents in related compounds |
| Prior Art |
Limited direct prior art on the exact process |
Similar synthesis methods in the field could challenge novelty |
Key Takeaways
- U.S. Patent 9,421,280 covers a specific, optimized process for synthesizing a heterocyclic drug compound, emphasizing yield, purity, and fewer steps.
- The claims are narrow, focused on process details and intermediates, limiting broad infringement claims.
- The patent landscape indicates a competitive environment with ongoing innovation in heterocyclic synthesis, supported by multiple related patent filings.
- Enforcement activity is minimal; the patent's primary value lies in process exclusivity rather than broad chemical protection.
- The patent will remain in force until 2034, providing a significant competitive barrier in this drug synthesis space.
FAQs
1. Can this patent be circumvented by developing an alternative synthetic route?
Yes. The narrow scope of claims on specific process steps allows for design-around strategies, including starting from different intermediates or employing alternative catalysts.
2. Is the patent's protection limited to specific reagents and conditions?
Yes. The claims specify particular reagents, catalysts, solvents, and reaction conditions, limiting infringement to processes using these parameters.
3. Are there any ongoing litigations or challenges to this patent?
No public records indicate active litigation as of February 2023.
4. How does this patent impact the development of similar drugs?
It potentially blocks competitors from using the patented synthesis method, encouraging alternative synthetic approaches or licensing negotiations.
5. What is the expiration date of this patent?
Expected to expire on August 16, 2034, assuming no maintenance fee non-payment or extensions.
References
[1] United States Patent and Trademark Office. (2016). U.S. Patent 9,421,280. Retrieved from USPTO database.
[2] WIPO. (2017). Patent Landscape Report on Heterocyclic Synthesis. Retrieved from WIPO PATENTSCOPE.
[3] European Patent Office. (2020). Patent family analysis for heterocyclic compounds. EPO Patent Information.
[4] PatentScope. (2022). Litigation and patent status reports. WIPO.
